RAC reborn as NExTRAC to advise NIH on safety, ethics of emerging technologies

After decades of waxing and waning authority over recombinant DNA and gene therapies, NIH's 45-year-old Recombinant DNA Advisory Committee is ending its reviews of individual clinical protocols and turning toward broader evaluation of newer technologies with ethical and safety concerns, including gene editing and synthetic

Read the full 452 word article

User Sign In